Traders panic as stocks, metals, crypto bleed
A global selloff is hitting markets hard after Trump’s tariffs, with Ethereum plunging and copper prices taking a dive.
Stockhead
Sleep device maker’s shares take tariff hit
The maker of sleep apnoea and other devices, Kiwi-based Fisher & Paykel Healthcare expects a Trump tariff hit because it manufactures in Mexico.
Guy on Rocks: Almonty Industries
Guy casts his gaze over Almonty Industries and two tungsten projects across Portugal and South Korea with great strategic importance.
Quarterlies: AI, semiconductors power tech gains
Tech small caps enjoyed strong interest in the December quarter as they pivoted to AI and semiconductor technology.
More Stories
Exploration maestro leads the band at Artemis
Pilbara gold explorer Artemis Resources has a new leader whose mine finding pedigree augurs well as it targets the next Hemi.
Optiscan kicks off GI study in Germany
Optiscan completes first gastrointestinal (GI) flexible prototype to collect images from the GI tract and activates GI study at major German university.
OZM’s high-grade gold hits excites punters
OzAurum’s high-grade drill hits at the Mulgabbie North project have identified a new zone that outlines its potential to host significant mineralisation.
Caprice targets maiden gold resource
Caprice has recommenced drilling at its promising Island gold project, which hosts historic workings just 12km from Ramelius’ Cue mine.
OZM hits high-grade gold at Mulgabbie North
Drill hits of up to 4m at 14.17g/t gold have led to OzAurum identifying a new high-grade target at its Mulgabbie North gold project.
Cash backs Indiana’s golden opportunity
Indiana Resources is a rare junior with massive cash backing, but its South Australian gold prospects could be the real value driver.
Paradigm eyes $110m raise with loyalty offer
Paradigm Biopharmaceuticals has launched loyalty options and piggyback options offers which could potentially raise more than $110 million.
How major commodities fared in 2024
Gold outshined the chasing pack as only a handful of commodities sailed through choppy economic waters unscathed in a tumultuous 2024.
Shares dive on Trump’s tariffs
The ASX has crashed today on Trump’s tariffs. Meanwhile oil has risen, crypto has absolutely face-planted and Novonix is up on an anti-China dumping win.
PAR picks Advanced Clinical for key trial
Paradigm Biopharmaceuticals has selected Advanced Clinical as the preferred clinical research organisation for the phase III trial for PARA_OA_012.
Original URL: https://www.ntnews.com.au/business/stockhead